Regadenoson
Pre-clinicalTerminated 0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Hypertension
Conditions
Pulmonary Hypertension
Trial Timeline
Aug 1, 2014 → May 25, 2017
NCT ID
NCT02220634About Regadenoson
Regadenoson is a pre-clinical stage product being developed by Astellas Pharma for Pulmonary Hypertension. The current trial status is terminated. This product is registered under clinical trial identifier NCT02220634. Target conditions include Pulmonary Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Hypertension were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
3
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02697877 | Pre-clinical | Completed |
| NCT02589977 | Approved | Completed |
| NCT02220634 | Pre-clinical | Terminated |
| NCT01969916 | Pre-clinical | Completed |
| NCT01779869 | Approved | Completed |
| NCT01618669 | Phase 3 | Completed |
| NCT01446094 | Approved | UNKNOWN |
| NCT01334918 | Phase 2 | Completed |
| NCT01021618 | Pre-clinical | Completed |
| NCT01026012 | Pre-clinical | Completed |
| NCT00881218 | Phase 1 | Completed |
| NCT00837369 | Phase 1 | Completed |
| NCT00871260 | Approved | Completed |
| NCT00857792 | Pre-clinical | Completed |
Competing Products
20 competing products in Pulmonary Hypertension